Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
affinitac + docetaxel
- Development stage
- Unknown
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Affinitac + docetaxel is a combination therapy under investigation for the treatment of advanced non-small cell lung cancer (NSCLC). Affinitac is an antisense oligonucleotide designed to inhibit the expression of specific genes involved in cancer cell survival and proliferation. Docetaxel is a semisynthetic taxane that acts as a microtubule inhibitor, stabilizing microtubules and preventing their depolymerization, which leads to cell cycle arrest and apoptosis. The combination aims to enhance antitumor efficacy by targeting complementary pathways involved in tumor growth and resistance. Clinical trials have evaluated this regimen in patients with previously treated NSCLC[1].
02
Targets
TUBB (Tubulin (alpha and beta subunits))BCL-2 (BCL-2 family)
Beyond the preview
Go deeper on affinitac + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on affinitac + docetaxel.